How COVID-19 is changing the production of cell therapies

Implementation of contingency plans allows for continued progress in therapy development

May 21, 2020 · Cell Sourcing, Industry Updates, Supply Chain

Managing donor collections during the COVID-19 pandemic

Why a diverse apheresis center network is critical to business continuity

April 10, 2020 · Cell Sourcing, Q&A, Supply Chain

Are ‘super donors’ the answer to sustainable growth for the allogeneic cell and gene therapy industry?

Why reliance on a small subset of donors could introduce risk for companies

March 12, 2020 · Cell Sourcing

Navigating a time-sensitive cell therapy supply chain during the coronavirus outbreak (Updated)

Why established systems and relationships matter

February 20, 2020 · Industry Updates, Q&A, Supply Chain

HLA matching could bring more allogeneic cell therapies to market, faster

An expert opinion on HLA matching relevance for allogeneic cell therapies

February 10, 2020 · Cell Sourcing, Emerging Science, Industry Updates

Advancements in Cell and Gene Therapy: 2019 Year-in-Review

January 8, 2020 · Emerging Science, Industry Updates

Quality Starting Material: The Driving Force Behind Life-Saving Cell Therapies

By Jamie Margolis, PhD, Senior Vice President of Donor Services, NMDP/Be The Match

December 20, 2019 · Cell Sourcing

Cell collection standards for cell therapies

A case study from the Standards Coordinating Body developed in partnership with Be The Match BioTherapies

December 5, 2019 · Gene therapy, Industry Updates, Supply Chain